German drugmaker Merck has today raised its 2026 core profit guidance for the third time this year, helped by better underlying performance, foreign exchange effects and the acquisition of US firm Bio-Techne.
The pharmaceutical company benefits from a high demand for artificial intelligence and medicines for rare diseases. Merck performed better than expected in the third quarter.
(Teleborsa) - Merck KGaA has raised for the third time the forecasts on profits for the whole year, supported by the good results of the division dedicated to laboratory equipment and a decrease, lower...
Thanks to AI-Boom and Life Science, Merck exceeds expectations in the third quarter. The Dax Group is raising its forecast for 2026, which increases Merck's share.
The German company Merck announced the third consecutive upgrade of its annual forecasts for profitability and net sales, now setting the target of adjustments